Gastric Cancer Clinical Trials in Nashville, Tennessee
19 recruitingNashville, Tennessee
Showing 1–19 of 19 trials
Recruiting
Phase 2Phase 3
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled370 locationsNCT06203600
Recruiting
Phase 1
A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without Bevacizumab, in Participants With Advanced or Metastatic Solid Tumors
Metastatic Hepatocellular CarcinomaLocal Advanced Hepatocellular CarcinomaAlpha-fetoprotein (AFP)-Producing Gastric Cancer+2 more
BeOne Medicines140 enrolled20 locationsNCT06427941
Recruiting
Phase 1
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Esophageal CancerGastric CancerCervical Cancer+5 more
Genentech, Inc.450 enrolled41 locationsNCT05581004
Recruiting
Phase 3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
Esophageal CancerGastric CancerGastroesophageal Junction Adenocarcinoma
AstraZeneca2,130 enrolled258 locationsNCT07431281
Recruiting
Phase 3
A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric Cancer
Gastroesophageal Junction AdenocarcinomaHER2-positive Gastric Cancer
AstraZeneca840 enrolled286 locationsNCT06764875
Recruiting
Phase 1
A Phase 1/1b Study of IAM1363 in HER2 Cancers
HER2-positive Breast CancerHER2 + Breast CancerHER2 Mutation-Related Tumors+10 more
Iambic Therapeutics, Inc383 enrolled48 locationsNCT06253871
Recruiting
Phase 2
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Breast CancerEsophageal CancerGastric Cancer+1 more
Jazz Pharmaceuticals200 enrolled21 locationsNCT06695845
Recruiting
Phase 1
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+7 more
SystImmune Inc.280 enrolled17 locationsNCT06293898
Recruiting
Phase 2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
Gastric CancerOvarian CancerEndometrial Cancer+1 more
AstraZeneca454 enrolled95 locationsNCT05489211
Recruiting
Phase 2
A Study of Disitamab Vedotin With Other Anticancer Drugs in Solid Tumors
Metastatic Breast CancerBreast NeoplasmsGastroesophageal Junction Adenocarcinoma+7 more
Seagen, a wholly owned subsidiary of Pfizer172 enrolled139 locationsNCT06157892
Recruiting
Phase 3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Gastric Cancer
Daiichi Sankyo726 enrolled250 locationsNCT06731478
Recruiting
Phase 1
Study of TJ033721 (Givastomig) in Subjects With Advanced or Metastatic Solid Tumors
Gastric CancerEsophageal AdenocarcinomaMetastatic Cancer+5 more
I-Mab Biopharma US Limited330 enrolled21 locationsNCT04900818
Recruiting
Phase 3
A Phase Ⅲ Clinical Study of HLX22 in Combination With Trastuzumab and Chemotherapy for the Treatment of Gastroesophageal Junction and Gastric Cancer
Gastric CancerGastroesophageal-junction CancerHER2-positive Gastric Cancer+1 more
Shanghai Henlius Biotech550 enrolled208 locationsNCT06532006
Recruiting
Phase 2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+11 more
Daiichi Sankyo740 enrolled84 locationsNCT06172478
Recruiting
Phase 1
IKS014 in Advanced Solid Tumors That Express HER2
Breast CancerGastric CancerGastroesophageal-junction Cancer
Iksuda Therapeutics Ltd.165 enrolled12 locationsNCT05872295
Recruiting
Phase 1
A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4
Gastric CancerCervical CancerCancer+7 more
Rondo Therapeutics149 enrolled2 locationsNCT07218003
Recruiting
Phase 1
A Study of XMT-2056 in Advanced/Recurrent Solid Tumors That Express HER2
HER2-positive Breast CancerHER2-positive Colorectal CancerHER2-positive Gastric Cancer+2 more
Mersana Therapeutics162 enrolled14 locationsNCT05514717
Recruiting
Phase 1Phase 2
Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
Breast CancerEsophageal CancerGastric Cancer+4 more
ModeX Therapeutics, An OPKO Health Company115 enrolled6 locationsNCT06239194
Recruiting
Phase 2
Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer
Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+28 more
Academic and Community Cancer Research United116 enrolled15 locationsNCT04660760